Your session is about to expire
← Back to Search
Lucitanib for Solid Tumors
Study Summary
This trial is testing a new cancer drug, lucitanib, to see if it is safe and effective when used with nivolumab to treat advanced solid tumors. The trial will also look at whether it matters if patients take the drug with or without food.
- Solid Tumors
- Gynecologic Cancers
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Is this a recent clinical trial?
"Lucitanib has been under investigation for a little over a decade. In 2010, the first clinical trial evaluating Lucitanib's safety and efficacy was conducted. This study, sponsored by Medarex, enrolled 127 patients. After the initial study in 2010, Lucitanib was approved for Phase 1 clinical trials. Presently, there are 753 live studies involving Lucitanib being conducted in 2357 cities across 50 different countries."
Are there any ongoing or previous studies that have used Lucitanib?
"As of now, 753 different active clinical trials are researching Lucitanib. Out of these, 84 have reached Phase 3. Additionally, while there are many trials based out of Ciudad de Mexico and Maryland, 40516 different locations are running clinical trials for Lucitanib."
What is the total number of volunteers for this clinical trial?
"This trial is not seeking new participants at the moment. The listing was created on 29th July 2019 and was last updated on 21st July 2020. There are 2630 other cancer trials and 753 Lucitanib trials currently looking for patients."
What are the common diseases that Lucitanib is used to target?
"Lucitanib can be used as an effective treatment against malignant neoplasms, unresectable melanoma, and squamous cell carcinoma."
Share this study with friends
Copy Link
Messenger